Pranlukast

Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

Product Specifications

CAS Number

[103177-37-3]

Product Name Alternative

ONO-1078

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Endogenous Metabolite; Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pranlukast.html

Purity

99.61

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(NC1=C2C(C(C=C(C3=NNN=N3)O2)=O)=CC=C1)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4

Molecular Formula

C27H23N5O4

Molecular Weight

481.50

Precautions

H315, H319

References & Citations

[1]Obata T, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992 Nov;60 (3) :227-37.|[2]Fang SH, et al. Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells. Acta Pharmacol Sin. 2012 Dec;33 (12) :1511-7.|[3]Ogata M, et al. Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun. 1992 Jun;60 (6) :2432-7.